Roche Reports Results of Tecentriq in P-III IMvigor130 Study for Previously Untreated Advanced Bladder Cancer

 Roche Reports Results of Tecentriq in P-III IMvigor130 Study for Previously Untreated Advanced Bladder Cancer

Shots:

  • The P-III IMvigor130 study involves assessing of Tecentriq + platinum-based CT vs platinum based-CT as monothx. in 1213 patients with metastatic urothelial carcinoma (mUC) prior not treated with systemic therapy
  • The P-III IMvigor130 study resulted in meeting its 1EPs of PFS with the reduction in the risk of disease worsening or death, improved OS and no new safety signals were observed
  • Tecentriq (atezolizumab) is a mAb targeting PD-L1, blocking its interaction with PD-1 and B7.1 receptors, being evaluated in four ongoing P-III studies for early and advanced bladder cancer and is an approved therapy for mUC, NSCLC, PD-L1+ triple-negative breast cancer

Click here to­ read full press release/ article | Ref: Roche | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post